$AKBA
Akebia Therapeutics, Inc.

2019 Q4 Form 10-Q Financial Statement

#000156459019042962 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q3
Revenue $69.60M $91.98M $53.17M
YoY Change 16.19% 72.99% 28.79%
Cost Of Revenue $38.15M $38.26M
YoY Change 391.08%
Gross Profit $39.50M $53.71M
YoY Change -26.17%
Gross Profit Margin 56.75% 58.4%
Selling, General & Admin $44.90M $34.18M $10.38M
YoY Change -18.51% 229.33% 54.9%
% of Gross Profit 113.67% 63.63%
Research & Development $80.40M $74.51M $70.63M
YoY Change -7.69% 5.49% 20.33%
% of Gross Profit 203.54% 138.72%
Depreciation & Amortization $9.690M $600.0K $200.0K
YoY Change 444.38% 200.0% 0.0%
% of Gross Profit 24.53% 1.12%
Operating Expenses $126.3M $109.6M $81.01M
YoY Change -11.21% 35.31% 23.76%
Operating Profit -$94.89M -$55.91M -$27.84M
YoY Change 5.25% 100.79% 15.17%
Interest Expense -$800.0K $228.0K $1.780M
YoY Change -147.06% -87.19% 111.4%
% of Operating Profit
Other Income/Expense, Net -$1.344M $43.00K $1.796M
YoY Change -176.1% -97.61% 72.36%
Pretax Income -$96.20M -$55.86M -$26.05M
YoY Change 8.82% 114.47% 12.76%
Income Tax -$1.752M -$1.277M $0.00
% Of Pretax Income
Net Earnings -$94.48M -$54.59M -$26.05M
YoY Change 57.33% 109.56% 12.59%
Net Earnings / Revenue -135.75% -59.35% -48.99%
Basic Earnings Per Share
Diluted Earnings Per Share -$791.5K -$459.2K -$456.1K
COMMON SHARES
Basic Shares Outstanding 118.9M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $147.7M $145.6M $375.2M
YoY Change -54.05% -61.19% 22.19%
Cash & Equivalents $147.4M $122.9M $162.4M
Short-Term Investments $245.0K $22.73M $212.7M
Other Short-Term Assets $6.600M $7.800M $6.700M
YoY Change -57.96% 16.42% 67.5%
Inventory $116.3M $116.0M
Prepaid Expenses
Receivables $38.86M $29.65M $688.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $309.5M $299.0M $397.5M
YoY Change -33.9% -24.78% 19.05%
LONG-TERM ASSETS
Property, Plant & Equipment $10.38M $12.80M $3.800M
YoY Change 29.38% 236.82% 11.76%
Goodwill $55.10M $55.05M
YoY Change 0.09%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $75.99M $97.91M $2.500M
YoY Change -44.55% 3816.28% 92.31%
Total Long-Term Assets $461.7M $496.2M $6.300M
YoY Change -12.61% 7776.38% 34.04%
TOTAL ASSETS
Total Short-Term Assets $309.5M $299.0M $397.5M
Total Long-Term Assets $461.7M $496.2M $6.300M
Total Assets $771.2M $795.2M $403.8M
YoY Change -22.61% 96.93% 19.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $39.22M $64.36M $12.70M
YoY Change -8.36% 406.79% 45.98%
Accrued Expenses $129.1M $126.6M $94.60M
YoY Change -14.48% 33.87% 342.06%
Deferred Revenue $39.83M $32.14M $70.10M
YoY Change -30.1% -54.15%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $208.1M $223.1M $177.4M
YoY Change -21.67% 25.79% 17.17%
LONG-TERM LIABILITIES
Long-Term Debt $75.81M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $30.22M $30.06M $83.90M
YoY Change 2.2% -64.17% -4.0%
Total Long-Term Liabilities $106.0M $30.06M $83.90M
YoY Change 258.53% -64.17% -4.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $208.1M $223.1M $177.4M
Total Long-Term Liabilities $106.0M $30.06M $83.90M
Total Liabilities $376.4M $327.7M $261.3M
YoY Change 4.39% 25.4% 9.47%
SHAREHOLDERS EQUITY
Retained Earnings -$794.1M -$699.6M
YoY Change 54.37%
Common Stock $1.189B
YoY Change 3.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $394.8M $467.6M $142.5M
YoY Change
Total Liabilities & Shareholders Equity $771.2M $795.2M $403.8M
YoY Change -22.61% 96.93% 19.26%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q3
OPERATING ACTIVITIES
Net Income -$94.48M -$54.59M -$26.05M
YoY Change 57.33% 109.56% 12.59%
Depreciation, Depletion And Amortization $9.690M $600.0K $200.0K
YoY Change 444.38% 200.0% 0.0%
Cash From Operating Activities -$92.13M $10.99M -$12.47M
YoY Change 25.02% -188.13% -77.17%
INVESTING ACTIVITIES
Capital Expenditures -$220.0K -$2.530M -$310.0K
YoY Change -73.49% 716.13% -47.46%
Acquisitions
YoY Change
Other Investing Activities $22.50M $26.92M $11.31M
YoY Change 28.21% 138.02% -125.5%
Cash From Investing Activities $22.28M $24.39M $11.01M
YoY Change 33.33% 121.53% -124.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 94.42M 190.0K 360.0K
YoY Change 117925.0% -47.22% -99.44%
NET CHANGE
Cash From Operating Activities -92.13M 10.99M -12.47M
Cash From Investing Activities 22.28M 24.39M 11.01M
Cash From Financing Activities 94.42M 190.0K 360.0K
Net Change In Cash 24.57M 35.57M -1.100M
YoY Change -143.18% -3333.64% -96.93%
FREE CASH FLOW
Cash From Operating Activities -$92.13M $10.99M -$12.47M
Capital Expenditures -$220.0K -$2.530M -$310.0K
Free Cash Flow -$91.91M $13.52M -$12.16M
YoY Change 26.15% -211.18% -77.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
Akebia Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001517022
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8756903
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
118943016
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22727000
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
245 First Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei Entity File Number
EntityFileNumber
001-36352
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122886000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104644000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
871-2098
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
216996000
CY2019Q3 us-gaap Inventory Net
InventoryNet
115987000
CY2019Q3 us-gaap Goodwill
Goodwill
55053000
CY2019Q3 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
300312000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
97907000
CY2019Q3 us-gaap Assets
Assets
795220000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
64362000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
126644000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
30060000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
29573000
CY2019Q3 us-gaap Liabilities
Liabilities
327658000
CY2018Q4 us-gaap Liabilities
Liabilities
360612000
CY2018Q4 us-gaap Inventory Net
InventoryNet
114245000
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29654000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16666000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7754000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15724000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147892000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
29162000
CY2018Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2019Q3 akba Amortization Of Intangible Assets Product
AmortizationOfIntangibleAssetsProduct
9101000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
38263000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74512000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70634000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34178000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
795220000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-514395000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
467562000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
635928000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
299008000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
468275000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12799000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8023000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30141000
CY2018Q4 us-gaap Goodwill
Goodwill
55053000
CY2018Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
328153000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
137036000
CY2018Q4 us-gaap Assets
Assets
996540000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
42796000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
150917000
CY2018Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
15000000
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
32142000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
56980000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
223148000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
265693000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3006000
CY2019Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
43887000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
55709000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28811000
CY2019Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1752000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
6631000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-261000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-699571000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
996540000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
118863735
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
116887518
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
118863735
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
116887518
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
91977000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53169000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
265446000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
79888000
CY2019Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
akba Amortization Of Intangible Assets Product
AmortizationOfIntangibleAssetsProduct
27301000
us-gaap Cost Of Revenue
CostOfRevenue
107189000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
242557000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
203955000
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10378000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
104537000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31940000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
314000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2494000
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36000
CY2018Q3 akba Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
267000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
59000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54207973
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83534000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1277000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4879000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
81012000
us-gaap Operating Expenses
OperatingExpenses
349654000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-54585000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-26047000
CY2019Q3 akba License Expense
LicenseExpense
929000
akba License Expense
LicenseExpense
2560000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
109619000
us-gaap Net Income Loss
NetIncomeLoss
-185176000
us-gaap Net Income Loss
NetIncomeLoss
-83534000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.57
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.54
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
118863063
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57027598
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
118071674
us-gaap Operating Expenses
OperatingExpenses
235895000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-55905000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27843000
us-gaap Operating Income Loss
OperatingIncomeLoss
-191397000
us-gaap Operating Income Loss
OperatingIncomeLoss
-88003000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
228000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1780000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1582000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4417000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-185000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-240000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55862000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26047000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-190055000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
267000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54602000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25997000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-184909000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-83501000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
122574000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
95416000
CY2018Q1 akba Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
218000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
182000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2232000
CY2018Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-108000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-23418000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
197096000
CY2018Q2 akba Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
-3000
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
91000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-34069000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
165923000
CY2018Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
50000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
142540000
CY2019Q1 akba Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
188000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
698000
akba Noncash Interest Expense
NoncashInterestExpense
508000
akba Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
-1673000
akba Fair Value Write Up Of Inventory Sold
FairValueWriteUpOfInventorySold
51604000
us-gaap Inventory Write Down
InventoryWriteDown
5968000
us-gaap Share Based Compensation
ShareBasedCompensation
6991000
us-gaap Share Based Compensation
ShareBasedCompensation
6978000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12988000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
42118000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-33528000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
28565000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-9415000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
346000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-3145000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-67000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
26438000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5686000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-29176000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
365000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2094000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
225000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-72421000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
566379000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9035000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
195000
CY2019Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
426000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2284000
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
59000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-58170000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
519356000
CY2019Q3 akba Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
195000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2613000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-17000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1659000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
638000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27301000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
795000
akba Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1577000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36660000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28101000
akba Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-131000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-165306000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23795000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6435000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
776000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
130610000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
180091000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
64721000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
13000000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
172438000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
188896000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19877000
akba Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
9035000
akba Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
95453000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
383000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
482000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
560000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
555000
akba Payments For Retirement Of Treasury Stock
PaymentsForRetirementOfTreasuryStock
426000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
15000000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
13000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5448000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96477000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18142000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
92559000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107099000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71437000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125241000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163996000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">1. Nature of Organization and Operations</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. <font style="Background-color:#FFFFFF;color:#000000;">Akebia is a biopharmaceutical company focused on the development and commercialization of therapeutics for people with kidney disease. Akebia&#8217;s commercial product, Auryxia<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (ferric citrate) is currently approved by the United States Food and Drug Administration, or FDA, and marketed for two indications in the United States, or the U.S.: the control of serum phosphorus levels in adult patients with chronic kidney disease, or CKD, on dialysis, or DD-CKD, and the treatment of iron deficiency anemia, or IDA, in adult patients with CKD not on dialysis, or NDD-CKD. </font>Ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with DD-CKD and NDD-CKD under the trade name Riona<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (ferric citrate hydrate) and is approved, but not currently marketed, in the European Union as an oral treatment for the control of hyperphosphatemia in adult patients with DD-CKD and NDD-CKD under the trade name Fexeric<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>(ferric citrate). <font style="Background-color:#FFFFFF;color:#000000;">The Company&#8217;s lead investigational product candidate, vadadustat, is an oral therapy in Phase 3 development for two indications: anemia due to CKD in adult patients with DD-CKD and anemia due to CKD in adult patients with NDD-CKD.&nbsp;&nbsp;The Company believes vadadustat has the potential to set a new standard of care in the treatment of anemia due to CKD, acting via a novel hypoxia-inducible factor, or HIF, pathway. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 11, 2019, the Company entered into a loan agreement, or the Loan Agreement, with Keryx as guarantor, Biopharma Credit plc as collateral agent and lender, or the Collateral Agent, and Biopharma Credit Investments V (Master) LP as lender, or collectively with the Collateral Agent, Pharmakon, pursuant to which term loans in an aggregate principal amount of $100.0 million are available to the Company in two tranches, subject to certain terms and conditions, or the Term Loan. Subject to the satisfaction of certain conditions, the first tranche of $80.0 million, or Tranche A, will be drawn in a single drawing on November 25, 2019, or the Tranche A Funding Date. The second&#160;tranche&#160;under the&#160;Term Loan&#160;allows the Company to borrow an additional $20.0 million until December 31, 2020, or Tranche B. Refer to Note 11 to our condensed consolidated financial statements in Part I, Item 1 &#8211; Financial Statements (unaudited) for additional details on the Loan Agreement.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On December 12, 2018, the Company completed a merger with Keryx Biopharmaceuticals, Inc., or Keryx, or the Merger. Pursuant to the terms and conditions of the Agreement and Plan of Merger, or the Merger Agreement, each share of Keryx common stock, or Keryx Share, issued and outstanding immediately prior to the effective time of the Merger, or the Effective Time, was cancelled and converted into 0.37433, or the Exchange Multiplier, fully paid and non-assessable shares of Akebia common stock, or Akebia Shares, resulting in the issuance of an aggregate of 59,270,410 Akebia Shares. </font> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, raising capital, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan to the Company&#8217;s Japanese partners <font style="Background-color:#FFFFFF;color:#000000;">Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively, JT and Torii,</font> on December 12, 2018. The Company has not generated a profit to date and may never generate profits from product sales. The Company&#8217;s product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market its product candidates. If the Company does not successfully commercialize any of its product candidates, it may be unable to achieve profitability.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects its cash resources, including funds to be received from its collaborators and $100.0 million upon closing of the Term Loans with Pharmakon, subject to the satisfaction of certain customary conditions, to fund the Company&#8217;s current operating plan beyond the next twelve months, into the first quarter of 2021. However, on a quarterly basis, the Company is required to conduct an accounting analysis under ASC 205-40, <font style="font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font>, or ASC 205-40. Under the accounting standards, a company is not permitted to include elements of its operating plan that are deemed to be &#8220;outside of the company&#8217;s control&#8221; in an ASC 205-40 analysis, even though certain of those elements may be appropriately included in the company&#8217;s cash runway analysis.&#160; For example, the Company&#8217;s cash runway includes receipt of a milestone payment from Mitsubishi Tanabe Pharma Corporation, or MTPC, upon manufacturing and marketing approval of vadadustat in Japan, but since receipt of that milestone payment is deemed to be &#8220;outside of the Company&#8217;s control&#8221; under the accounting standards, the Company is not permitted to include it in its ASC 205-40 analysis. The result of the Company&#8217;s ASC 205-40 analysis is that there is &#8220;substantial doubt&#8221; that the Company will have sufficient funds to satisfy its obligations through the next twelve months from the date of issuance of this Quarterly Report on Form 10-Q. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will require additional capital for the further commercialization of Auryxia and continued development and potential commercialization of the Company&#8217;s existing product candidates and would need to raise additional funds to pursue development activities related to any additional product candidates. If and until the Company can generate a sufficient amount of product revenue, the Company expects to finance future cash needs through public or private equity or debt transactions, payments from its collaborators, royalty transactions, strategic transactions, or a combination of these approaches. However, adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce or eliminate its research and development programs or any commercialization efforts.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, other non-current liabilities, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, inventories, income taxes, intangible assets and goodwill. </p>
akba Period For Funds Insufficient To Satisfy Obligations
PeriodForFundsInsufficientToSatisfyObligations
P12M
akba Closing Of Loan Agreement Subject To Satisfaction Of Customary Conditions
ClosingOfLoanAgreementSubjectToSatisfactionOfCustomaryConditions
100000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
162430000
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16416000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9981000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3617000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1958000
CY2019Q3 us-gaap Depreciation
Depreciation
600000
CY2018Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
1700000
us-gaap Depreciation
Depreciation
600000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y
CY2018Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
23737000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
80876000
akba Valuation Allowances And Reserves Adjustments Related To Prior Period Sales
ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
1520000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
25195000
akba Valuation Allowances And Reserves Deductions Related To Prior Period Sales
ValuationAllowancesAndReservesDeductionsRelatedToPriorPeriodSales
50083000
CY2019Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
30855000
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
76029000
CY2019Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
27095000
CY2018Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
53144000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
60441000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
110974000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
1254000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
6813000
akba Collaborative Arrangements Additional Cost Sharing Payments Expected Amount
CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount
63700000
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22721000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2019Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
122886000
CY2019Q3 akba Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
145607000
CY2019Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
145613000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
217257000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
262000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
104644000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
36402000
CY2019Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
300312000
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
329675000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1522000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
36401000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
328153000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
9100000
CY2019Q3 akba Finite Lived Intangible Assets Adoption Adjustment
FiniteLivedIntangibleAssetsAdoptionAdjustment
-540000
CY2018Q4 akba Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
321901000
CY2018Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
321640000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
22727000
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
223000
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
174456000
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
39000
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
29934000
CY2018Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
262000
CY2018Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
204390000
CY2019Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0
CY2018Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
51
CY2019Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2824000
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1880000
CY2019Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
152208000
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
215122000
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
45863000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
18182000
CY2019Q3 akba Inventory Net Current And Non Current
InventoryNetCurrentAndNonCurrent
200895000
CY2018Q4 akba Inventory Net Current And Non Current
InventoryNetCurrentAndNonCurrent
235184000
CY2019Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
84908000
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
120939000
CY2019Q3 us-gaap Inventory Write Down
InventoryWriteDown
2900000
CY2018Q3 us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
0
CY2018Q4 us-gaap Inventory Net
InventoryNet
0
CY2019Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
329675000
CY2019Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
28823000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
36402000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
36401000
CY2019Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
145606000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
527754000
CY2019Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
-472701000
CY2019Q3 akba Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
66194000
CY2018Q4 akba Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
71881000
CY2019Q3 akba Accrued Product Revenue Allowances Current
AccruedProductRevenueAllowancesCurrent
28408000
CY2018Q4 akba Accrued Product Revenue Allowances Current
AccruedProductRevenueAllowancesCurrent
22861000
CY2019Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
7740000
CY2018Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
9537000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4884000
CY2019Q3 akba Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
3352000
CY2018Q4 akba Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
6383000
CY2019Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2697000
CY2018Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2430000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2393000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2367000
CY2019Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1208000
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2255000
CY2019Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
926000
CY2018Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1088000
CY2018Q4 us-gaap Postemployment Benefits Liability Current
PostemploymentBenefitsLiabilityCurrent
3962000
CY2018Q4 akba Accrued Merger Costs Current
AccruedMergerCostsCurrent
16071000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8763000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12082000
CY2019Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
40000000
CY2019Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
29400000
CY2018Q4 us-gaap Line Of Credit
LineOfCredit
15000000
CY2019Q3 us-gaap Line Of Credit
LineOfCredit
0
CY2019Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
23528450
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14948900
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2613000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2252000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6991000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6978000
us-gaap Lessee Operating Lease Residual Value Guarantee Description
LesseeOperatingLeaseResidualValueGuaranteeDescription
The lease agreements do not contain residual value guarantees.
us-gaap Lessee Operating Lease Existence Of Residual Value Guarantee
LesseeOperatingLeaseExistenceOfResidualValueGuarantee
false
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1700000
us-gaap Operating Lease Cost
OperatingLeaseCost
5000000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1700000
us-gaap Operating Lease Payments
OperatingLeasePayments
5200000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1296000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7008000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7064000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6735000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5347000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
13934000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
41384000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7689000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
33695000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
6777000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
7008000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
7064000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
6735000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5347000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
13934000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
46865000
CY2019Q3 akba Purchase Committed Program Remaining Contract Costs
PurchaseCommittedProgramRemainingContractCosts
76900000
us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
52700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13128410
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5361401

Files In Submission

Name View Source Status
0001564590-19-042962-index-headers.html Edgar Link pending
0001564590-19-042962-index.html Edgar Link pending
0001564590-19-042962.txt Edgar Link pending
0001564590-19-042962-xbrl.zip Edgar Link pending
akba-10q_20190930.htm Edgar Link pending
akba-20190930.xml Edgar Link completed
akba-20190930.xsd Edgar Link pending
akba-20190930_cal.xml Edgar Link unprocessable
akba-20190930_def.xml Edgar Link unprocessable
akba-20190930_lab.xml Edgar Link unprocessable
akba-20190930_pre.xml Edgar Link unprocessable
akba-ex101_340.htm Edgar Link pending
akba-ex102_403.htm Edgar Link pending
akba-ex103_402.htm Edgar Link pending
akba-ex104_401.htm Edgar Link pending
akba-ex311_12.htm Edgar Link pending
akba-ex312_8.htm Edgar Link pending
akba-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending